Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 12;7:388. doi: 10.1038/s41597-020-00729-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article.

PMC Copyright notice

Fig. 1 — Construct design and crystallization of CysLT₁R and CysLT₂R. (a,b) Amino acid sequence snake-plot of the CysLT₁R (a) and CysLT₂R (b) crystallization constructs. Protein modifications are shown in red, red background shows stabilising point mutations, red font amino acids – linkers for BRIL insertion. Initial figure drawn using GPCRdb⁴⁹. The N-terminal peptide fragment (a) was added to both constructs. (c–h) microphotographs of typical crystals grown in lipidic cubic phase (LCP) for CysLT₁R-zafirlukast (c), CysLT₁R-pranlukast (d), and CysLT₂R with antagonists: 11a (C222₁ space group) (e), 11a (F222 space group) (f), 11b (g), and 11c (h) complexes⁵¹.